News & Events

News

Atlanta Nonprofit, Take Aim at Cancer, Completes Two Successful Educational Events

Take Aim at Cancer, an organization benefiting targeted therapy and lung cancer research, successfully presented two educational programs designed to educate the public on how researchers are closer than ever to eradicating this deadly disease. The completion of the events is the culmination of a four-year dream for Take Aim at Cancer’s Founder Jeff Wigbels. After being... read more

Take Aim at Cancer Presents a Feb. 2 Public Event: Innovations in Lung Cancer Research, Treatment and Patient Care

Leading MD Anderson Oncology Chief to Speak at The Lovett School at 7pm ATLANTA — Lung cancer is the No. 1 cause of cancer-related death in both men and women in the U.S. according to the Centers for Disease Control and Prevention. In 2007 (most recent statistics), lung cancer accounted for more deaths than breast cancer, prostate cancer and colon... read more

TakeAimAtCancer.org Launches Educational Arm

The Take Aim at Cancer Research Fund (TakeAimAtCancer.org), a non-profit organization benefitting lung cancer research, has launched its educational arm with the completion of a pilot program held at The Westminster Schools of Atlanta on February 3 and 4, 2011. Lead by Co-chairs Barbara Levy and Fontaine Draper, the mission of the organization’s educational arm is to empower communities with the tools and... read more

Take Aim at Cancer Founder to Speak at American Association for Cancer Research Annual Meeting

At the Washington Convention Center in Washington, D.C. on April 18, 2010, Take Aim at Cancer founder and cancer survivor, Jeff Wigbels, will participate in a panel discussion for the news media at the American Association for Cancer Research (AACR) Annual Meeting.   The session, entitled “Personalized Therapy of Advanced Non-Small Cell Lung... read more

Donate now to support targeted-therapy cancer research and treatment.

Survivor Wine - Prepare to toast to your health.

Researching and advancing molecular-level cancer therapy for promising results.